Trials / Unknown
UnknownNCT05020925
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
A Phase I/II, Open-label, Multi-center Trial to Investigate the Efficacy and Safety of SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-center, phase I/II study to evaluate the efficacy and safety of SHR-1701 in combination with famitinib in subjects with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 | Intravenous (IV) on Day 1 of each cycle |
| DRUG | Famitinib | Famitinib, po, qd |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2022-05-01
- Completion
- 2024-02-01
- First posted
- 2021-08-25
- Last updated
- 2021-08-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05020925. Inclusion in this directory is not an endorsement.